<DOC>
	<DOCNO>NCT00543062</DOCNO>
	<brief_summary>To assess safety Staccato Prochlorperazine cardiac repolarization ( QTc interval duration ) 2 dose level compare placebo healthy volunteer .</brief_summary>
	<brief_title>Staccato Prochlorperazine Thorough QT/QTc</brief_title>
	<detailed_description>The plan study single dose , double-blind , double-dummy , active placebo control , randomize , 4-period cross-over study investigate investigate 2 dos level Staccato Prochlorperazine , positive control know QT/QTc prolongation ( oral moxifloxacin ) , placebo .</detailed_description>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Prochlorperazine</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Male female subject age 18 65 year , inclusive . 2 . Body mass index ( BMI ) ≥21 ≤30 . 3 . Subjects willing able comply study schedule requirement , stay CRU 3day period 3 consecutive 2day period . 4 . Subjects speak , read , understand English willing able provide write informed consent IRB approve form prior initiation study procedure . 5 . Subjects good general health prior study participation determine detailed medical history , physical examination , 12lead ECG , blood chemistry profile , hematology , urinalysis , opinion Principal Investigator . 6 . Female participant ( childbearing potential sexually active ) male participant ( sexually active partner childbearing potential ) agree use medically acceptable effective birth control method throughout study one week follow end study . 1 . Subjects regularly consume large amount xanthinecontaining substance must exclude . 2 . Subjects take prescription nonprescription medication within 5 day Treatment Period 1 must exclude . 3 . Subjects acute illness within last 5 day Treatment Period 1 must exclude . 4 . Subjects smoke tobacco within last year must exclude . 5 . Subjects history HIV positivity must exclude . 6 . Subjects history allergy intolerance prochlorperazine phenothiazine must exclude . 7 . Subjects history contraindication anticholinergic must exclude . 8 . Subjects history pheochromocytoma , seizure disorder , Parkinson 's disease , Restless Leg Syndrome must exclude . 9 . Subjects ECG abnormality must exclude . 10 . Subjects history within past 2 year drug alcohol dependence abuse define DSM4 must exclude . 11 . Subjects history syncope , unstable angina , myocardial infarction ( within 6 month ) , congestive heart failure , transient ischemic attack , pheochromocytoma must exclude . 12 . Subjects history asthma chronic obstructive lung disease must exclude . 13 . Subjects hypotension ( systolic ≤90 mmHg , diastolic ≤50 mmHg ) , hypertension ( systolic ≥140 mmHg , diastolic blood pressure ≥90 mmHg ) must exclude . 14 . Subjects test positive alcohol positive urine drug screen must exclude . 15 . Female subject positive pregnancy test screen randomization visit , breastfeed must exclude . 16 . Subjects receive investigational drug within 30 day prior Screening Visit must exclude . 17 . Subjects consider investigator , reason , unsuitable candidate receiving prochlorperazine , unable use inhalation device , must exclude . 18 . Subjects disease ( ) , history , physical examination , laboratory abnormality ( ALT AST &gt; 2fold upper limit normal , bilirubin &gt; 1.5 mg/dL , creatinine &gt; 1.8 mg/dL ) investigator 's opinion present undue risk subject may confound interpretation study result must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>